Synaps Dx
Latest round
- Series A
Last raised
- Sep 2021
Total raised
- Undisclosed
Investors
- 1
About Synaps Dx
Synaps Dx, founded in 2016, is based in Rockville, US. The company focuses on developing diagnostic solutions for Alzheimer's disease, aiming to provide healthcare professionals with tools that facilitate timely and accurate diagnoses. The company has completed 2 deals to date, with their latest deal occurring on October 12, 2021.Synaps Dx specializes in advanced diagnostics for Alzheimer's disease, focusing on providing precise and early diagnostic tools to enhance patient care. The company’s primary offerings include innovative testing solutions designed to identify biomarkers associated with Alzheimer's, facilitating timely diagnosis and management of the condition. These diagnostic services are tailored to healthcare providers, including neurologists and primary care physicians, aiming to support their clinical decision-making processes. The products are utilized across North America and select regions in Europe, reaching a diverse range of end-users, from healthcare institutions to patients and their families.Synaps Dx operates through a model that emphasizes partnerships with healthcare providers and institutions, facilitating the integration of their diagnostic solutions into clinical settings. Revenue is generated through direct transactions with these healthcare entities, which may include fee-for-service agreements for diagnostic tests and related services. The company also engages in collaborative efforts with research institutions and pharmaceutical companies, enhancing its service offerings while expanding its customer base. Specific pricing structures for their diagnostic products are established based on the complexity of the tests and the associated clinical value, ensuring that clients receive tailored solutions that meet their needs.In the coming years, Synaps Dx plans to scale up production of DISCERN™, its first autopsy-validated, highly accurate, minimally invasive test for the definitive diagnosis of Alzheimer's disease versus other forms of non-Alzheimer's dementias. Synaps Dx is also looking to expand its footprint into additional geographic regions beyond North America and Europe, though specific target markets have not been disclosed. The anticipated growth reflects the company’s commitment to advancing its diagnostic capabilities and improving patient outcomes.
Who invested in Synaps Dx
1 investor across 1 round
See all investors in Synaps Dx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 30, 2021
Amount
Undisclosed
Investors
Questions about Synaps Dx
Who invested in Synaps Dx?
Synaps Dx has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Synaps Dx raised?
Synaps Dx has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Synaps Dx last raise money?
Synaps Dx's most recent round on record is a Series A, in Sep 2021.
What does Synaps Dx do?
Synaps Dx, founded in 2016, is based in Rockville, US.
Where is Synaps Dx headquartered?
Synaps Dx is headquartered in Rockville, US.
Which VCs invest in companies like Synaps Dx?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Synaps Dx's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Synaps Dx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.